Kala Pharmaceuticals to Present at Jefferies Healthcare Conference
June 02, 2022 08:00 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.
May 23, 2022 00:01 ET
|
Kala Pharmaceuticals, Inc.
--Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments----Kala Will Focus Resources on Phase 2/3 Trial of KPI-012 for Orphan Disease...
Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022 07:00 ET
|
Kala Pharmaceuticals, Inc.
- Expanded Coverage for EYSUVIS® to 92% of Total Commercial Lives and 30% of All Medicare Lives - - Achieved 18% EYSUVIS Prescription Growth in 1Q 2022 - - Presented KPI-012 Phase 1b...
Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call
May 09, 2022 08:00 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®
May 03, 2022 08:00 ET
|
Kala Pharmaceuticals, Inc.
--Now Covered by the largest Pharmacy Benefit Manager in the United States and Humana Medicare----Expands Commercial coverage to 92% of total commercial lives----Doubles Medicare coverage from 7.1...
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting
May 01, 2022 09:00 ET
|
Kala Pharmaceuticals, Inc.
-- Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up ---- All Patients with...
Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting
April 04, 2022 16:01 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and...
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 29, 2022 07:00 ET
|
Kala Pharmaceuticals, Inc.
-- Achieved $11.2 Million in Net Revenue in 2021 ---- Expanded Coverage for EYSUVIS® to 118 Million Commercial Lives and 7.1 Million Medicare Lives ---- KPI-012 Phase 1b Clinical Data Accepted for...
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call
March 23, 2022 08:00 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and...
Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare
March 08, 2022 08:00 ET
|
Kala Pharmaceuticals, Inc.
-- Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives -- ARLINGTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a...